je.st
news
Tag: clinical
Cavion to Present Clinical Trial Data at ASCO
2015-05-29 02:53:23| Logistics - Topix.net
Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors and neurologic diseases, announced today that Matthias Holdhoff, MD, PhD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will present preliminary results from an ongoing multi-site National Cancer Institute Adult Brain Tumor Consortium and Cavion-sponsored Phase 1b clinical trial at the 2015 Annual Meeting of the American Society of Clinical Oncology on June 1. This dose escalation trial, which completed enrollment in November 2014, evaluates the safety and pharmacokinetics of Cavion's novel cancer drug mibefradil when sequentially administered with temozolomide in patients with recurrent high-grade glioma.
Tags: data
present
trial
clinical
Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)
2015-05-28 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Mercks R&D and NanoStrings Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NSTG Exchange: NASDAQ read more
Tags: for
research
development
program
Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015
2015-05-27 21:43:05| Logistics - Topix.net
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago. "I am impressed by the excellent long-term cardiac safety profile we're seeing in patients who have undergone treatment with aldoxorubicin across several cancer types," said Sant P. Chawla, M.D., F.R.A.C.P., Principal Investigator and Director of the Sarcoma Oncology Center.
Tags: data
positive
presented
clinical
Leading Cancer Centers To Present Clinical Utility Data for Guardant360A At ASCO
2015-05-27 13:10:29| Logistics - Topix.net
This toolset includes: Tumor Response Map: A powerful new visual language of tumor genomics, helping to unify the representation of tumor genomics, heterogeneity and clinical response over time. Enhanced Guardant360 Report: By using the Tumor Response Map and the alteration-specific trend line, the report offers a visual representation of changes and trends in patients' sequential tests, allowing them to quickly see a summary of all detected somatic cfDNA alterations and their quantitative burden, along with available therapeutics and clinical trials.
Tags: data
present
leading
cancer
Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW
2015-05-19 09:30:24| Biotech - Topix.net
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease . As per the CTA filing, the intended clinical study of ALN-AAT will be performed in normal healthy volunteers, and, then, in subjects with alpha-1 liver disease.
Tags: data
application
files
trial
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »